Vaccines for covid-19 patients
If you want to see all comparisons, please click here
ChAdOx1 vs MenACWY
The Evidence profile and Summary of Findings table were updated on January 25th, 2021.You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
| Trial | Comparisons | Design | Participants | Sample size | Overall risk of bias Primary outcome |
Full description | |
|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | ||||||
| NCT04324606; ISRCTN15281137; EudraCT 2020-001072-15 University of Oxford/AstraZeneca Folegatti PM (COV001), Lancet, 2020 Full text Barrett JR, Nature medicine, 2020 Full text Ewer KJ, Nature medicine, 2020 Full text Commentary Commentary |
ChAdOx1 | MenACWY | RCTPhase 1/2 | Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK | N=1077 |
Low Details |
|
| NCT04400838
University of Oxford/AstraZeneca Voysey M (COV002), Lancet, 2020 Full text Commentary |
ChAdOx1 LD/SD | 1/2 doses MenACWY | RCTPhase 2/3 | Healthy adults in 18 centers in the UK | N=7548 |
Some concerns Details |
Full description |
| ChAdOx1 SD/SD | 1/2 doses MenACWY | ||||||
| ISRCTN89951424 University of Oxford/AstraZeneca Voysey M (COV003), Lancet, 2020 Full text Commentary |
ChAdOx1 SD/SD | MenACWY/saline | RCTPhase 3 | Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil | N=4088 |
Some concerns Details |
|
| NCT04444674 University of Oxford/AstraZeneca Voysey M (COV005), Lancet, 2020 Full text Commentary |
ChAdOx1 std 2 doses | Saline | RCTPhase 1/2 | Healthy adults from four studies in multiple centres in Brazil, South Africa, and the UK | N=2013 |
Details |
|
The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.
We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.